Baseline Circulating Tumor Cell (CTC) Count As a Prognostic Marker of PSA Response and Progression in Metastatic Castrate Sensitive Prostate Cancer (mcspc): Results from SWOG S1216, a Phase III Randomized Trial of Androgen Deprivation Plus Orteronel (cyp17 Inhibitor) or Bicalutamide.
JOURNAL OF CLINICAL ONCOLOGY（2023）
Key words
Metastatic Prostate Cancer
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined